Myszkowski Kenneth Allen's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Jan 7, 2025
- Accession no.
- 0001628280-25-000805
- Filed
- Jan 7, 2025
- Trade date
- Jan 4-7, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $893.1K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Myszkowski Kenneth AllenCIK 0001486672 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2025 | Common Stock | AGrant or awardAcquired | +100,000 | $0.00 | $0 | 500,600 | Direct | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −17,765 | $19.68 | −$349,615.2 | 482,835 | Direct | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −9,402 | $20.10 | −$188,980.2 | 473,433 | Direct | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −8,000 | $19.70 | −$157,600 | 465,433 | Direct | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −10,000 | $19.69 | −$196,900 | 455,433 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.